Sigrid therapeutics shares
Unlisted company
Sigrid's business model is based on the patented SiPore platform, a materials technology with applications in metabolic health, oral care and veterinary medicine. The company commercialises the technology through two product lines: SiPore21, classified as a medical device for prediabetes and diabetes, and Carb Fence (formerly Glucose Stabiliser), a consumer supplement for blood sugar control and weight management. Unlike pharmaceutical weight-management treatments, which often act systemically by affecting hormones or appetite signalling, SiPore is a non-pharmaceutical technology that acts locally in the gut without systemic absorption.
Clinical evidence and research
The clinical evidence base includes several completed clinical trials, including the SHINE study, one of the world's largest clinical studies in prediabetes. The technology is based on more than 15 years of research at Stockholm University under the leadership of co-founder Tore Bengtsson.
Two parallel growth tracks
The company is growing organically through two parallel tracks. The first is the in-house commercialisation of its consumer products, with Sigrid expanding distribution from its own e-commerce channel to pharmacy chains and healthcare provider platforms in Sweden, the UK and the US. The second track is the licensing of the SiPore platform to international consumer health companies for applications outside the core business, with an exclusive global licensing agreement in oral care as the first step. In parallel, work is under way to obtain regulatory approval for SiPore21 as a medical device in the EU and as a medical food in the US.
Business model characteristics
SiPore platform: metabolic health, oral care, veterinary medicine
Non-pharmaceutical, acts locally in the gut
Clinical evidence from four trials, including SHINE
Products and growth
Two product lines: SiPore21 and Carb Fence
15+ years of research, broad patent portfolio
In-house commercialisation and licensing
Financial performance
Published 14 September 2026Published figures from the company’s own reports. Amounts in MSEK · change from the previous year
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Net sales | 13(+648 %) | 1.7 | 0 | – |
| Revenue growth | 648% | – | – | – |
| EBITDA | -21 | -44 | -31 | -22 |
| EBIT | -22 | -44 | -32 | -22 |
| Net income | -22 | -43 | -31 | -22 |
| Equity | 36(+65.5 %) | 21(-66.3 %) | 64(+26.4 %) | 50(-17.6 %) |
| Cash and bank | 18(-17.7 %) | 22(-64.7 %) | 62(+54 %) | 41(-34.2 %) |
Documents and reports
4New share issues
Latest 1An overview of the company’s capital raising.
| Date | Capital raised | Valuation |
|---|---|---|
| SEK 9m | SEK 595m |
Questions about Sigrid therapeutics
Is Sigrid Therapeutics publicly listed?
No, Sigrid Therapeutics is a private company and is not publicly listed. The company has not completed an IPO, so its shares are not traded on a regulated stock exchange, but rather on the private market.
What does Sigrid Therapeutics do?
Sigrid Therapeutics develops and commercializes non-pharmaceutical products for blood sugar control and weight management based on its patented SiPore technology. The technology is based on bioengineered porous silica, and the products are aimed at people with prediabetes, type 2 diabetes, and excess weight.
Can I buy shares in Sigrid Therapeutics?
Yes, it is possible to buy shares in Sigrid Therapeutics through trading in unlisted shares, provided that there are sellers. Via Eqvor, you can place a buy order and be matched with sellers in the unlisted market.
How do I sell shares in Sigrid Therapeutics?
If you own shares in Sigrid Therapeutics, you can place a sell order through Eqvor and be matched with buyers. Once the transaction has been completed, the shares are transferred in accordance with the company’s Euroclear-linked custody structure.
Is Sigrid Therapeutics affiliated with Euroclear?
Yes, Sigrid Therapeutics is affiliated with Euroclear. This means that the shares are handled within the Swedish securities system and can be delivered to a custody account with any bank or investment firm once the transaction has been completed.
Can I hold Sigrid Therapeutics shares with Avanza or Nordnet?
Yes, since Sigrid Therapeutics is affiliated with Euroclear, the shares can normally be held in a securities account with, for example, Avanza or Nordnet, provided that the bank or online broker supports the custody of unlisted shares.
Does Sigrid Therapeutics have any right-of-first-offer or pre-emption clauses?
No, according to the company information, Sigrid Therapeutics does not have any right-of-first-offer or pre-emption provisions. This means that share transfers do not normally need to be offered to existing shareholders before being sold to an external buyer.
At what price is the Sigrid Therapeutics share traded?
Since Sigrid Therapeutics is not publicly listed, there is no official share price on a regulated marketplace. Instead, the price is determined by supply and demand among buyers and sellers in the private market.
When will Sigrid Therapeutics be listed on the stock exchange?
There is currently no publicly announced timetable for a stock market listing of Sigrid Therapeutics. We therefore do not currently know when Sigrid Therapeutics may be listed or whether the company will carry out an IPO.
What are the risks of investing in Sigrid Therapeutics?
Investing in Sigrid Therapeutics involves risk, just like other investments in unlisted shares. The company’s valuation may be affected by clinical evidence, regulatory processes, commercialisation, patents, capital requirements, competition, and demand for products for blood sugar control, weight management, and metabolic health. Trading in unlisted shares also normally involves lower liquidity than trading in listed shares.
Where can I find Sigrid Therapeutics' annual report?
Sigrid Therapeutics' annual report is available under Investor Relations and Financial Reports. The company's annual reports and other financial reports are available there for download.
Has Sigrid Therapeutics carried out any share issues?
Yes, Sigrid Therapeutics has carried out capital raises and previous new share issues. Sigrid Therapeutics Capital raised is stated as SEK 252.4 million, indicating how much capital the company has raised through previous financing.
How much capital has Sigrid Therapeutics raised in total?
Sigrid Therapeutics' Capital raised is stated as SEK 252.4 million. An equity raise is a term for raising capital, but terms such as funding round, financing, or share issue are often used.
Has Sigrid Therapeutics reported a profit or a loss?
Sigrid Therapeutics reports a negative result in the latest available information. Under Key figures, EBITDA is stated as TSEK -43,618 and net income as TSEK -43,107. The company’s earnings performance is also shown in the Results per year graph.